These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 31059004)

  • 21. MicroRNA‑126‑3p inhibits the proliferation, migration, invasion, and angiogenesis of triple‑negative breast cancer cells by targeting RGS3.
    Hong Z; Hong C; Ma B; Wang Q; Zhang X; Li L; Wang C; Chen D
    Oncol Rep; 2019 Oct; 42(4):1569-1579. PubMed ID: 31364749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
    Gameiro SR; Malamas AS; Tsang KY; Ferrone S; Hodge JW
    Oncotarget; 2016 Feb; 7(7):7390-402. PubMed ID: 26862729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twist1 accelerates tumour vasculogenic mimicry by inhibiting Claudin15 expression in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Sun H; An J; Lin X; Zhu D; Zhao X; Wang X; Liu F; Zhang Y; Liu J; Gu Q; Dong X; Qiu Z; Liu Z; Qi H; Che N; Li J; Cheng R; Zheng X
    J Cell Mol Med; 2020 Jul; 24(13):7163-7174. PubMed ID: 32469152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling.
    Sankar AP; Cho HM; Shin SU; Sneh T; Ramakrishnan S; Elledge C; Zhang Y; Das R; Gil-Henn H; Rosenblatt JD
    Cancer Res Commun; 2024 Mar; 4(3):738-756. PubMed ID: 38315147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
    Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
    J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
    M JR; S V
    Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Knockdown of ZEB1 suppressed the formation of vasculogenic mimicry and epithelial-mesenchymal transition in the human breast cancer cell line MDA-MB-231.
    Liang W; Song S; Xu Y; Li H; Liu H
    Mol Med Rep; 2018 May; 17(5):6711-6716. PubMed ID: 29512767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelium-Dependent Induction of Vasculogenic Mimicry in Human Triple-Negative Breast Cancer Cells Is Inhibited by Calcitriol and Curcumin.
    Morales-Guadarrama G; Méndez-Pérez EA; García-Quiroz J; Avila E; García-Becerra R; Zentella-Dehesa A; Larrea F; Díaz L
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
    Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
    Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
    Wang S; Huang J; Lyu H; Lee CK; Tan J; Wang J; Liu B
    Cell Death Dis; 2013 Mar; 4(3):e556. PubMed ID: 23519125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR‑33a‑5p‑LDHA axis.
    Bai X; Jiang H; Han G; He Q
    Mol Med Rep; 2019 Aug; 20(2):1857-1865. PubMed ID: 31257519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
    Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
    Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
    Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.
    Bissanum R; Lirdprapamongkol K; Svasti J; Navakanitworakul R; Kanokwiroon K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):256-262. PubMed ID: 29024629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constructing a novel prognostic model for triple-negative breast cancer based on genes associated with vasculogenic mimicry.
    Ren Y; Feng L; Tan Z; Zhou F; Liu S
    Aging (Albany NY); 2024 May; 16(9):8086-8109. PubMed ID: 38728245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells.
    Aikins AR; Kim M; Raymundo B; Kim CW
    Exp Biol Med (Maywood); 2017 Mar; 242(6):573-583. PubMed ID: 28058861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TARBP2 promotes tumor angiogenesis and metastasis by destabilizing antiangiogenic factor mRNAs.
    Zhou M; Lu W; Li B; Liu X; Li A
    Cancer Sci; 2021 Mar; 112(3):1289-1299. PubMed ID: 33484209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
    Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
    Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.